Republic Services Inc. Common Stock vs Twist Bioscience Corp — how do they compare? Republic Services Inc. Common Stock trades at $226.9 (market cap $68.73B), while Twist Bioscience Corp trades at $141 (market cap $9.82B). The key difference: Republic Services Inc. Common Stock is far larger — about 7× Twist Bioscience Corp's market cap, and Republic Services Inc. Common Stock pays a 1.19% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| RSG | TWST | |
|---|---|---|
Market Cap | $68.73B | $9.82B |
Volume | 1,226,777 | 2,115,226 |
Sector | Industrials | Health |
52-Week High | $232.27 | $205.00 |
52-Week Low | $197.73 | $25.45 |
Enterprise Value | $82.91B | $9.75B |
Dividend Yield | 1.19% | — |
Typical Hold Time | — | 27 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Twist Bioscience (TWST) trades at $151.33, down 0.35% on the day, with a bullish technical signal but negative profitability. Revenue growth is strong, increasing from $204M in 2022 to $377M in 2025, yet net losses persist. Recent news highlights a partnership with Eli Lilly's TuneLab AI platform, boosting investor optimism. The stock is near its consensus price target of $153.70, with institutional buying noted in Q2 2026.
Outlook remains speculative; growth prospects from AI-driven drug discovery are promising, but profitability challenges and cash burn pose significant risks. Analyst consensus is bullish (73% buy ratings), yet high valuation multiples and consistent earnings misses warrant caution for investors seeking near-term returns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Republic Services Inc. is a waste management company that provides non-hazardous solid waste collection, transfer, disposal, and recycling services across North America.
Read more on RSG →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →